BioSpace News Archive

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the presentation of six posters at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) today announced an update on the National Institute on Drug Abuse (NIDA)-funded trial evaluating BXCL501 (sublingual dexmedetomidine) as a potential treatment for opioid use disorder (OUD).

Medicenna Therapeutics Corp. announced that new clinical data from the Phase 1 monotherapy dose escalation/evaluation portion of the Phase 1/2 ABILITY-1 study evaluating MDNA11, the only long-acting, ‘beta-enhanced not-alpha’ interleukin-2 super-agonist in clinical development, in patients with advanced solid tumors, were presented at the 38th Annual Meeting of the SITC held in San Diego, CA, on November 4th, 2023.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2023.

Instil Bio, Inc. reported two poster presentations at the SITC 2023 Annual Meeting demonstrating that its proprietary CoStimulatory Antigen Receptor platform enhances the activity of CD4+ T cells across multiple axes.

InspireMD, Inc., developer of the CGuard™ Embolic Prevention Stent System for treatment of carotid artery disease and prevention of stroke announced financial results and business updates for the third quarter ended September 30, 2023.

Biotheus Inc. (“Biotheus”) today announced that the company has entered into an exclusive global license and collaboration agreement under which BioNTech will be developing, manufacturing and commercializing PM8002 globally ex-Greater China, whereas Biotheus retains the rights to exploit PM8002 in Greater China.

Galvanize Therapeutics, Inc. unveiled compelling data from the INCITE-ES clinical study at the recent Society for Immunotherapy for Cancer (SITC) conference.

Compugen Ltd. (Nasdaq: CGEN) (TASE:CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced data presented at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held on November 1-5, 2023.

Karyopharm Therapeutics Inc. announced the presentation of updated long-term safety and efficacy data from a pre-specified exploratory subgroup analysis of the SIENDO study in patients with advanced or recurrent TP53 wild-type endometrial cancer at the International Gynecological Cancer Society Annual Global Meeting in Seoul, South Korea.